Press coverage about Rite Aid (NYSE:RAD) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rite Aid earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.0722097953862 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Rite Aid Announces Intent to Redeem All of Its Outstanding 9.25% Senior Notes Due 2020 (markets.financialcontent.com)
- Analysts Recommendations Rite Aid Corporation (RAD) – Newburgh Gazette (newburghgazette.com)
- OppenheimerFunds Inc. Has $104.23 Million Holdings in Rite Aid Co. (RAD) – Newburgh Gazette (newburghgazette.com)
- Cigna agrees to buy Express Scripts for $67 billion – CNNMoney (money.cnn.com)
- Health insurer Cigna set to buy Express Scripts: WSJ – Reuters (reuters.com)
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Rite Aid from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr cut shares of Rite Aid from a “strong-buy” rating to a “buy” rating and set a $2.47 price objective on the stock. in a report on Thursday, January 11th. Evercore ISI assumed coverage on shares of Rite Aid in a research note on Thursday, January 4th. They set an “underperform” rating and a $1.50 target price on the stock. Finally, Deutsche Bank assumed coverage on shares of Rite Aid in a research note on Monday, December 4th. They set a “hold” rating and a $2.25 target price on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Rite Aid presently has a consensus rating of “Hold” and an average target price of $2.75.
COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/2018/03/14/rite-aid-rad-receiving-somewhat-favorable-news-coverage-study-shows/1890239.html.
About Rite Aid
Rite Aid Corporation is a retail drugstore chain. The Company’s segments include Retail Pharmacy and Pharmacy Services. The Company operates under The Rite Aid name. It operates approximately 4,560 stores in over 30 states across the country and in the District of Columbia. The Company’s Retail Pharmacy segment consists of Rite Aid stores, RediClinic and Health Dialog.
Receive News & Ratings for Rite Aid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rite Aid and related companies with MarketBeat.com's FREE daily email newsletter.